Among cancer patients prescribed oxycodone, a cross-sectional multicenter study revealed no statistically significant variance in serum oxymorphone concentrations between CYP2D6 ultrarapid metabolizers and normal metabolizers [61]. This evidence concerns the gene CYP2D6 and cancer.